Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells
文献类型：期刊论文
| 作者 | Sun, Xu2; Lou, Li-Guang1 ; Sui, Dong-Hu2; Wu, Xiao-Hua3
|
| 刊名 | ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
 |
| 出版日期 | 2014 |
| 卷号 | 15期号:22页码:9939-9943 |
| 关键词 | Lobapaltin preclinical activity ovarian carcinoma |
| ISSN号 | 1513-7368 |
| DOI | 10.7314/APJCP.2014.15.22.9939 |
| 文献子类 | Article |
| 英文摘要 | Lobaplatin, one of the third - generation platinum compounds, has shown encouraging anticancer activity in a variety of tumor types. However, the efficacy of lobaplatin in ovarian cancer has not been systemically evaluated. In this study, lobaplatin as a single agent and in combination with taxanes was investigated in - vitro and in an in vitro model of ovarian carcinoma. Using the sulforhodamine B (SRB) assay, the cytotoxic effects of lobaplatin alone and in combination with taxanes were compared with cisplatin and carboplatin in seven ovarian cancer cell lines. In addition, in - vitro antitumor activities were evaluated with cisplatin - sensitive and cisplatin - resistant human ovarian cancer xenografts in nude mice. The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with IC50 values from 0.9 to 13.8 mu mol/L in a variety of ovarian cancer cells. The combination of lobaplatin with docetaxel yielded enhanced cytotoxic activity in vitro. In addition, in platinum - sensitive ovarian cancer xenografts, lobaplatin alone showed similar antitumor activity to cisplatin and carboplatin. Furthermore, lobaplatin alone or in combination with docetaxel exhibited significant activity in platinum - resistant ovarian cancer xenografts. These results indicate that the use of lobaplatin alone or in combination with docetaxel might be a rational and novel therapeutic strategy for ovarian cancer. Further clinical development of lobaplatin is clearly warranted. |
| WOS关键词 | PRIMARY HEPATOCELLULAR-CARCINOMA ; ANTITUMOR-ACTIVITY ; ARTERIAL CHEMOEMBOLIZATION ; PHASE-II ; CANCER ; CARBOPLATIN ; CISPLATIN ; D-19466 ; TRIAL ; LINES |
| 资助项目 | Hainan Changan International Pharmaceutical Corporation Limited[00000000] ; Science and Technology Department of Guizhou Province of China[2011-5068] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000351056900066 |
| 出版者 | ASIAN PACIFIC ORGANIZATION CANCER PREVENTION |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/277244]  |
| 专题 | 药理学第一研究室 |
| 通讯作者 | Lou, Li-Guang |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China 2.Guizhou Yibai Pharmaceut Co Ltd, Clin Dept, Guiyang, Peoples R China; 3.Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200433, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Sun, Xu,Lou, Li-Guang,Sui, Dong-Hu,et al. Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,2014,15(22):9939-9943. |
| APA | Sun, Xu,Lou, Li-Guang,Sui, Dong-Hu,&Wu, Xiao-Hua.(2014).Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells.ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,15(22),9939-9943. |
| MLA | Sun, Xu,et al."Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells".ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 15.22(2014):9939-9943. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。